Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Highlights from MPN sessions

Raajit Rampal • 14 Dec 2021
ASH 2021
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Systemic Mastocytosis

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, summarizes some interesting highlights from the myeloproliferative neoplasm (MPN) sessions at ASH 2021. Dr Rampal draws focus on the number of therapeutic agents that are progressing in the treatment landscape of rare diseases including myelofibrosis, essential thrombocythemia, polycythemia vera, mastocytosis, and FGFR1-rearranged myeloid lymphoid disease. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.

More from Raajit Rampal

Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 24 Nov 2022
1:00
How genomic testing has influenced treatment approaches and clinical trial design in MPNs
Raajit Rampal • 26 Aug 2022
1:05
Venetoclax-based combinations in patients with accelerated and blast-phase MPNs
Raajit Rampal • 26 Aug 2022
0:46
The prognostic impact of TP53 mutation in MPNs
Raajit Rampal • 26 Aug 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals